Expiring patents are expected to contribute billions of dollars towards the loss of revenue of drug manufacturers in the years to come. To save itself from
Compound interest ought to be the rule rather than the exception in calculating prejudgment interest in litigation involving commercial businesses. It is welcoming to see
In Teva Pharmaceuticals USA Inc v Sandoz Inc, a patent infringement case evolved into an opportunity for the Supreme Court of the United States (SCOTUS)